press information / news
Genetic Factors Drive Roles of Gut Bacteria in Diabetes and Obesity
Neuherberg & Boston, September 9, 2015. A study of scientists at Helmholtz Zentrum München and Joslin Diabetes Center examines how bacterial and mammalian genomics interact to boost insulin resistance and other metabolic disorders. The results were published in the journal Cell Metabolism.
The trillions of bacteria in our digestive system play a major role in our metabolism, and they’re linked to risks of type 2 diabetes, obesity and the related conditions that make up “metabolic syndrome,” which has become a global health epidemic. Humans and animal models with diabetes and obesity have different gut bacteria than those who don’t, and when scientists transfer microbiota from obese humans or animals to germ-free animals, the recipients are more likely to become obese or diabetic.
Now in experiments in mice recently reported in Cell Metabolism, researchers in the team of Dr. Siegfried Ussar at Helmholtz Zentrum München and his colleagues at Joslin Diabetes Center in Boston have highlighted the ways in which the host’s genes interact with the microbial genes to create such conditions. “As a result, we found that one strain of mice which were genetically prone to become obese became resistant to excess weight gain after their populations of gut microbiota were transformed simply by sharing an environment with other mice”, says senior author C. Ronald Kahn, M.D., Chief Academic Officer at Joslin Diabetes Center and Mary K. Iacocca Professor of Medicine at Harvard Medical School.
“Kind of a designer probiotic”
These scientists also were able to identify certain bacterial strains that appear to play a positive or negative role in diabetes, obesity or related metabolic disorders, depending, in part, on the host animal’s genetic makeup. “Our hope is that if we can identify causal bacteria in these animal models, then we can look in humans for bacteria that serve the same kinds of function,” says Dr. Kahn. “The goal ultimately would be to get a cocktail of purified microbes that is optimized for treatment of humans with obesity or diabetes—kind of a designer probiotic.”
The scientists found that the three common mouse models—one prone to obesity and diabetes, one prone to obesity but not diabetes, and one resistant to both conditions—originally held very different populations of microbes in their guts. When the mice went on a high-fat diet, all of them saw dramatic change in their microbial populations. Over time, these populations became more similar among all the mice and their descendants, held in the same animal facility. “However, when you change the microbes it has different effects on different mice, depending on the mouse’s genetic background,” Kahn says. “Some animals, and presumably some people, will have much more metabolic syndrome with certain microbes than other animals.”
The Joslin researchers bred new generations of the three mice models and then tested whether germ-free mice who were given microbes from these three strains of mice were prone to diabetes or obesity like the donors. Following such direct transfer of microbes, some diabetes-resistant mice gained weight and had higher glucose levels. In other animals, “even metabolically bad bacteria didn’t cause a bad problem,” Dr. Kahn says. “They were only a problem if the animal had the genetic susceptibility to let those bacteria grow and cause their effect.”
Pinpointing strains that correlate very strongly with obesity
DNA sequencing employed in the study can identify about 3,000 different bacteria in the mouse gut, of which about 300 are fairly abundant, says Dr. Kahn. Sequencing can quantify how populations of specific bacterial strains vary under given experimental conditions, allowing the investigators to look for connections with disorders in the mice. Experiments in this field generally analyze the roles of groups of bacteria rather than individual strains. But the Joslin investigators pinpointed certain strains that correlate very strongly with conditions such as obesity and high blood glucose levels, suggesting that these strains help to cause those conditions.
The team plans to give germ-free mice some of these individual bacterial strains to see if they do help to drive changes in insulin sensitivity and other metabolic parameters. The scientists also will examine the results of altering microbiota populations in other ways, such as giving the mice antibiotics.
Ussar, S. et al. (2015). Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome, Cell Metabolism, DOI: 10.1016/j.cmet.2015.07.007
As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.
The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).
The German Center for Diabetes Research (DZD) is a national association that brings together experts in the field of diabetes research and combines basic research, translational research, epidemiology and clinical applications. The aim is to develop novel strategies for personalized prevention and treatment of diabetes. Members are Helmholtz Zentrum München – German Research Center for Environmental Health, the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition in Potsdam-Rehbrücke, the Paul Langerhans Institute Dresden of the Helmholtz Zentrum München at the University Medical Center Carl Gustav Carus of the TU Dresden and the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the Eberhard-Karls-University of Tuebingen together with associated partners at the Universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich.
Scientific contact at Helmholtz Zentrum München:
Dr. Siegfried Ussar, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Institute for Diabetes and Obesity, Ingolstädter Landstr. 1, 85764 Neuherberg - Phone +49 89 3187 2047 - E-mail